Omrix Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the development and marketing of biological products for the biosurgical and passive immunotherapy markets. Its biosurgical product is a fibrin sealant used for hemostasis in surgical procedures and is marketed as Crosseal in the United States and as Quixil outside of the United States. The company’s passive immunotherapy products include Intravenous immunoglobulin, a product primarily used to provide ongoing treatment for primary immune deficiencies by providing a selection of antibodies that mimic a healthy immune system; Vaccinia immunoglobulin (VIG), a product designed to treat smallpox vaccine-related...